Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today Inspire scientists and collaborators will present data from the denufosol tetrasodium cystic fibrosis (CF) program in a poster presentation at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) October 15 - 17, 2009 in Minneapolis, MN.
The poster, “Pharmacological Treatment of CF: Lessons Learned from a Phase 3 Clinical Trial” (T. Navratil, A. Schaberg, D. Mathews, C. Deans, T. Durham, F.J. Accurso), will be presented in Exhibit Hall B during the formal poster sessions on Thursday, October 15 from 11:50 am - 1:50 pm and Friday, October 16 from 7:00 am - 8:30 am local time. The poster describes the treatment regimen for a young, relatively mild patient population using a sample of 175 CF patients who were assigned to placebo in TIGER-1, Inspire’s first Phase 3 clinical trial with denufosol.
“This analysis highlights the use of numerous medications that treat the respiratory conditions resulting from CF. These important findings underscore the need for early intervention disease-modifying therapies that may reduce the need for multiple pharmacological treatments,” stated Frank J. Accurso, M.D., Head of Pulmonary Medicine, Director of Cystic Fibrosis Center at University of Colorado, Denver, and the lead principal investigator for TIGER-1.
The poster presentation will be available on Inspire’s website, www.inspirepharm.com, following the conference.